Trends in Tissue Engineering in 2018 * Opportunity & Innovations in the field of Regenerative Medicine

Tissue Engineering & Regenerative Medicine Patent Trends 2018

The field of regenerative medicine has exploded in the last decade. Regenerative medicine is a new way to cure patients besides traditional medicine and surgery. Regenerative medicine harnesses, in a clinically targeted manner, the ability of stem cells (i.e., the unspecialized master cells of the body) to renew themselves indefinitely and develop into mature specialized cells.

Regenerative medicine, Regenerative medicine patents, Regenerative medicine patent attorney, Regenerative medicine patent lawyer

What will be the Future Trends in Genomics?

The current clinical strategy primarily focuses on treating the symptoms of the disease. But with the rise in chronic diseases and organ failure, there is a large opportunity for regenerative medicines. Regenerative medicine is the future to treat current ailments. Stem cells have the ability to divide indefinitely, and to specialize into specific types of cells therefore, the regenerative medicine seeks to replace tissue or organs that have been damaged by disease, trauma, or congenital issues with the goal to cure previously untreatable injuries and diseases.


Stem cell therapy has been in development since the 1950s, and since then, new advancements and innovations in the field of regenerative medicines are coming up to provide solutions to some of the most challenging medical problems faced by humankind.  Regenerative medicines include pharmaceuticals, biopharmaceuticals, medical devices, cell therapies and some non-cell based treatments and have some of the most fascinating opportunities and hopes in regards to previously incurable diseases.

Patent Research , Research Litigation, Regenerative Medicine

Recent Patents filed in the field of “REGENERATIVE MEDICINE” domain

International Patent number WO/2017/221155 titled “AUTOMATED CELL PROCESSING SYSTEMS AND METHODS” was filed by GENESIS TECHNOLOGIES LIMITED having a patent publication date: 28 Dec 2017. The patent innovation provides systems and methods for automated cell processing of biological samples. The biological samples are the cells for use in cell therapy and regenerative medicine.

Systems for automated processing of batches derived from biological samples includes a closed and sterile enclosure; a plurality of reagent containers; at least one reagent dispenser; a quality control module for analyzing at least one characteristic of a batch; a harvesting module; a robotic module; and a control unit (CU) communicatively coupled to the at least one reagent dispenser, the quality control module, the harvesting module and the robotic module for controlling the automatic processing of batches. The automatic processing may be executable without handling by a human operator. The system may be configured to automatically process the plurality of batches without cross-contamination between batches, e.g., under GMP conditions.

International Patent number WO/2017/205541 titled “GROWTH-FACTOR NANOCAPSULES WITH TUNABLE RELEASE CAPABILITY FOR BONE REGENERATION” was filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA having a patent publication date 30 Nov 2017.

The International Patent relates to growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited by short in vivo half-lives and a narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. A nanoscale controlled release system (degradable protein nanocapsule) is provided via in-situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes are achieved with the growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 (BMP-2) nanocapsules.

3. WO/2017/223373


Assignee: CITY OF HOPE

Publication Date: 28 Dec 2017


Disclosed herein are methods of treating Canavan disease in a subject through restoring ASPA enzymatic activities in the subject by expressing exogenous wild type ASPA gene in the brain of the subject. Also disclosed are a process of producing neural precursor cells, including NPCs, glial progenitor cells and oligodendroglial progenitor cells, which express an exogenous wild type ASPA gene and the neural precursor cells produced by this process.

Patent validity litigation will be more in Genomics.

4. WO/2017/218846



Publication Date: 21 Dec 2017


The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.

5. US 20170296587



Publication Date: 19 Oct 2017


Disclosed are compositions of matter, protocols, and methods of treatment of neurological manifestations using stem cells, stem cell stimulators, and combination treatments. In one embodiment, a patient suffering neurological manifestations of a viral infection is administered a therapeutically active dose(s) of mesenchymal stem cells at a frequency and concentration sufficient to induce amelioration, remission or cure of neurological manifestations.

6. US 9763877

Title: Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract

Assignee: EndoCellutions, Inc.

Publication Date: 19 Sep 2017


The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes.

7. WO/2017/189842



Publication Date: 2 Nov 2017


The invention provides methods for treating a patient suffering from a disease or condition or age-related symptom that is caused by stem cell dysfunction or increased senescence. The methods comprise administering to the patient a composition comprising extracellular vesicles obtained from stem cells or serum of a subject that is younger or healthier than, and of the same species as, the patient.

8. US 9821026

Title: Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit

Assignee: Instituto de Medicina Molecular

Publication Date: 21 Nov 2017


The present disclosure relates to the use of RET, a transmembrane tyrosine kinase receptor, agonist molecules for Haematopoietic Stem Cell (HSC) expansion protocols and HSC transplantation therapy.

RET signaling molecules are expressed by HSCs and Ret ablation leads to reduced HSC numbers. RET signals provide HSCs with critical Bcl2 and Bcl2l1 surviving cues, downstream of p38/MAP kinase and CREB activation. Accordingly, enforced expression of RET downstream targets, Bcl2 or Bcl2l1, is sufficient to restore the activity of Ret null progenitors in vivo. Remarkably, activation of RET improves HSC survival or maintenance and in vivo transplantation efficiency, thus opening new horizons to the usage of RET agonist in HSC expansion and transplantation protocols.

Additionally, the present disclosure describes a kit comprising RET agonist molecules, to be used in HSC expansion protocols and transplantation therapy.

Prity Khastgir and her team of thinking geeks provides patent research Litigation Research services for global clients for over a decade. Intellectual property strategy for regenerative medicine for research worldwide research organisations. Our patent attorneys and patent agents in India specialize in biotech disciplines, including proteomics, tissue engineering & environmental biology. The research attorneys, patent agents, and thinking geeks include experienced client advocates representing a scope of disciplines from across the biotech sector in India.

Internet Business, Internet Business lawyer, Internet Business attorney

Leave a Reply

Your email address will not be published. Required fields are marked *